13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Pacific-R

    Acronym: 

    Pacific-R

    ACTRN/NCT /ethics: 

    NCT03798535

    Scientific title: 

    First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase All phases Tumour Stream Non-small cell lung cancer (NSCLC)
    Age Range 18 years and older Cancer Stage Locally Recurrent or Locally Advanced
    Sex Both Anticipated Start Date 2018-12-19
    Molecular Target Anticipated End Date 2023-12-01
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-small cell lung cancer (NSCLC)
    Cancer Stage Locally Recurrent or Locally Advanced
    Anticipated Start Date 2018-12-19
    Anticipated End Date 2023-12-01

    Trial Summary

    This is a non-interventional/observational cohort of NSCLC unresectable stage III patients treated with durvalumab. The study will be carried out as a retrospective review of established medical records for a subset of unresectable stage III patients treated with durvalumab.

    Lay Summary

    First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy

    Sponsor / Cooperative group

    AstraZaneca

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary Central Districts Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Dr Rohit Joshi Recruiting
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Dr Shawgi Sukumaran Not Yet Recruiting